Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
ALTER-L043
SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.
- NCT05351788 ↗
- Recruiting
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Focused
We haven't built an HCP commentary report on ALTER-L043 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ALTER-L043 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase Ⅱ Clinical Study of Combination Therapy of SKB264 in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- SKB264; KL-A167; Carboplatin; Cisplatin
- Arms
- SKB264+KL-A167 · Experimental
- SKB264+KL-A167+ Carboplatin or Cisplatin (EGFR wide type) · Experimental
- SKB264+KL-A167+ Carboplatin or Cisplatin (EGFR mutation) · Experimental
- Enrollment
- 110 (estimated)
- Primary outcomes
- Incidence and severity of adverse events (AEs)
- Objective Response Rate (ORR)
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Start
- May 20, 2022
- Primary completion
- Aug 2026 (estimated)
- Results posted
- No
- Registry record
- NCT05351788 · updated May 12, 2026
Publications
linked from the registry- Hong S, Wang Q, Cheng Y, Luo Y, Qu X, Zhu H, Ding Z, Li X, Wu L, Wang Y, Hu S, Wang E, Liu A, Sun Y, Fan Y, Ye F, Lu K, Fang J, Shen Y, Jin X, Ge J, Zhang L, Fang W. First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial. Nat Med. 2025 Nov;31(11):3654-3661. doi: 10.1038/s41591-025-03883-5. Epub 2025 Aug 19. PubMed 40830660